November 5, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX: PP) (“Pipex”), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced the presentation of preliminary results using its lead anti-copper drug candidate, COPREXA (oral tetrathiomolybdate), in the most commonly utilized transgenic pre-clinical murine model of Alzheimer’s Disease (AD) at the 2007 Society for Neuroscience annual meeting on November 4th in San Diego, CA... Pipex Pharmaceuticals' Press Release -Tuesday, November 6, 2007
Pipex Pharmaceuticals, Anti-Copper COPREXA Demonstrates 40% Reduction of Insoluble Amyloid Beta in Animal Models of Alzheimer’s Disease
November 5, 2007 -- Pipex Pharmaceuticals, Inc. (AMEX: PP) (“Pipex”), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced the presentation of preliminary results using its lead anti-copper drug candidate, COPREXA (oral tetrathiomolybdate), in the most commonly utilized transgenic pre-clinical murine model of Alzheimer’s Disease (AD) at the 2007 Society for Neuroscience annual meeting on November 4th in San Diego, CA... Pipex Pharmaceuticals' Press Release -
